Aligos Therapeutics reports a narrower Q2 GAAP loss and revenue exceeding forecasts by $2.5M, signaling stronger financial performance.
Aligos Therapeutics reported a Q2 GAAP loss of $2.21 per share, beating expectations by $0.04. Revenue reached $2.83M, surpassing estimates by $2.5M, driven by higher-than-anticipated operational activity.
Analysts had projected a wider loss and lower revenue for the quarter. The company’s prior quarter saw a loss of $2.50 per share on revenue of $0.3M, highlighting significant sequential improvement.
Shares showed limited movement in after-hours trading as investors digested the results.